ATNM Investors are Reminded of the Class Action Against Actinium Pharmaceuticals, Inc.: Contact Robbins LLP for Information About How to Become Lead Plaintiff for the Class

SAN DIEGO, April 14, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Actinium Pharmaceuticals, Inc. (NYSE: ATNM) securities between October 31, 2022 and August 2, 2024. Actinium is a late-stage biopharmaceutical company that develops targeted radiotherapies, such as Iomab-B, to treat people who have failed existing oncology therapies.For more information, submit a form, email attorney Aaron Dumas, ...